All Episodes
Mendelspod Podcast — 574 episodes · page 1 of 6
How Roswell Park Is Rethinking Molecular Testing for Blood Cancers with Sean Glenn
Building a Single Cell Atlas of the Poplar Tree with Robin Buell and Anita Giabardo
Three Illumina 5-Base Grant Contest Winners Share Cancer Research Insights from Combining Epigenetics and Genetics
Ten Years Ago Mike Joyner Was Skeptical of Precision Medicine. What Does He Say Today?
Deeper into the Genome: Google DeepMind’s Ziga Avsec on the New AlphaGenome Atlas
Mass Spec Comes to the Routine Core Lab: Don Mason of Roche on a New Era in Clinical Testing
Jennifer Dionne Wants to Read the Whole Proteome Using Nanophotonics, i.e. Raman Spectroscopy
Katie Maloney, Partner at DeciBio Consulting, Sees an Inflection Point for Digital and Computational Pathology
It’s One of the Greatest Success Stories of Molecular Medicine. Genomics Historian Kevin Davies on His Latest Book about Casgevy and Sickle Cell Disease
Elias Sayour on the Cancer Vaccine Breakthrough
What Single Cell Sequencing Revealed About Pulmonary Fibrosis with Nick Banovich, TGen
The Quest to Measure Protein Function with Polly Fordyce, Stanford
Doubling Down on Long Reads: New CEO of PacBio, Mark Van Oene
Serge Saxonov on What’s Next for 10x Genomics
“You Cannot Discover What You Cannot Make”: Lee Cronin on Programming Chemistry
All of Us Comes of Age. And So Does Its Funding: Josh Denny on the Next Phase of Precision Medicine
Season Opener: Is Biology Having Its Newtonian Moment? with Rob Phillips, Caltech
From the Archives: Erdinc Sezgin and the Physics of Living Cells
From the Archives: How Cellanome Is Changing the Way We Study Cell Function with Matthew Spitzer and Pier Federico Gherardini
Agilent and Oxford Nanopore Discuss Bringing Long Reads to the Clinic with a Customer
Liquid Biopsy for the Tumor Microenvironment: with Vince Miller and Mirna Jarosz
Can Liquid Biopsy Transform Chronic Disease? Hamed Amini and Soheil Damangir of Hepta
The UAE’s Big Bet on Genomic Medicine with Mohamed Alameri and Albarah El-Khani
Ryan Flynn of Harvard on Non-Coding RNA
Gary Schroth on Connecting Cellular Behavior to the Transcriptome
Two-Thirds of High-Risk Breast Cancer Patients May Avoid Chemotherapy According to Veracyte Data Presented at ASCO
Building the Diagnostic Layer of Modern Cancer Care with Rita Shaknovich and Karina Kulangara of Agilent
Mapping the Multi-Omic Era with Eric Green of Illumina
Inside Proteomics at Thermo Fisher with Yan Zhang
Separating Epigenetic Signals Improves Early Cancer Detection with Rob Osborne, Biomodal
Digital Controls for Cancer Drug Trials? Irina Babina, Concr
Solexa Co-Inventor Shankar Balasubramanian on Six-Base Sequencing and What's Next in Genomics
The Next Frontier in Biology: Physics? Erdinc Sezgin of the Karolinska Institute
The Case for a 6-Base Genome with Peter Fromen, CEO of Biomodal
The Eligible But Under-Tested: Genomic Medicine in 2026 with Damon Hostin, Illumina
Spatial Transcriptomics Is Changing How We Do Biology: Fei Chen, The Broad Institute
Beyond GLP-1: Why Peptides Are Back at the Center of Drug Discovery with Charlie Johannes and Tomi Sawyer
From the Archives: Inventor Mark Kokoris Debuts Roche’s New SBX Sequencer
Why Do Some Animals Live Ten Times Longer? Pursuing the Science of Aging with Steve Austad
MRD Testing: From Residual Disease to Real Decisions with Chris Hourigan and Gary Pestano
Early vs Late Recurrence: How Multimodal AI Is Changing Breast Cancer Prognosis with George Sledge, Caris Life Sciences
The Dark Genome with Author Sudhakaran Prabakaran
Illumina's New Mapped Read Technology Provides Insights into Rare Disease: Stephen Kingsmore, Olivia Kim-McManus and Ali Crawford
CareDx’s Second Act with CEO John Hanna
Inside GP2: Building a Global Genetic Map of Parkinson’s with Andrew Singleton and Ignacio Mata
A Simple Sponge, a Big Shift in Cell Therapy with Yev Brudno, UNC
How Cellanome Is Changing the Way We Study Cell Function with Matthew Spitzer and Pier Federico Gherardini
From Hereditary Risk to Residual Disease: Natera’s Integrated Vision for Precision Oncology with Adam ElNaggar, MD
The Rise of Geroscience with Alan Landay and Tom Blackwell, UTMB
Unlocking the RNA Revolution: How Self-Replicating RNA Could Transform Vaccines and Therapeutics with Andrew Geall, Replicate Bioscience
From Targets to Hits: The Emerging AI Ecosystem in Drug Discovery with Aqib Hasnain, Mithrl and Cheng Hu, Technetium Therapeutics
Most Popular Show of 2025: How Certis Is Rewriting Cancer Models with CEO Peter Ellman
Building the Front-End for Every Sequencer with Volta Labs CEO Udayan Umapathi
A New Foundational Platform for Biology: Cellanome’s Debut with CEO Omead Ostadan
The Best of Times, the Worst of Times: Former NHGRI Director Eric Green on a Shaken NIH and Surging Genomic Science
From the Archives: Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz
Petter Brodin of Karolinska: How Spatial Interactomics Could Transform Autoimmune Therapy
From GWAS to EWAS: Chirag Patel and and Gary Miller on the Rise of Exposomics
Agilent Partners with PacBio to Speed Adoption of Long Reads into Diagnostic Testing
How AI Is Doing Science with Vivek Adarsh, CEO of Mithrl
Inventor Mark Kokoris on Roche’s New Sequencing by Expansion
From Brewing Sake to Brewing Science: Takara Bio’s Bold New Chapter with CSO Andrew Farmer
How Pathologists Can Lead in Precision Medicine with David Braxton
From DNA to Proteins: Illumina Makes Its Proteomics Play - with Krishna Morampudi
Theranos Had the Vision. Truvian Has the Execution. Our Chat with CEO Jay Srinivasan
Physicians Don't Want a Laundry List of Genes says Premal Shah, CEO of Myome
The Customer Case for iconPCR with Stefan Green and Yann Jouvenot
Alex Dickinson on Long Read Sequencing, Multi Omics, and the Next Frontier in Genomics
Rapid Answers for Rare Disease: Katherine Stueland on GeneDx’s Mission
Moran Snir's Vision for Making Genomic Care Routine across the U.S.
How Certis Is Rewriting Cancer Models with CEO Peter Ellman
Myriad’s Next Chapter: New CEO Sam Raha on Growth, AI, and MRD Testing
Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz
Bodour Salhia and Danielle Goldberg: Rethinking Cancer Research with Illumina's 5-Base Solution
Reinventing PCR: Pranav Patel, N6 Tec
Making Whole Genome Sequencing the Universal Genetic Test - with David Ledbetter, Pediatric Rare Disease Institute, FSU
Remembering Atul Butte with Marina Sirota, Chirag Patel and Mike Snyder
The Age of Digital Pathology with Andy Beck, PathAI
What’s New for Regulatory Informatics in the Age of AI? Not Much—And That’s the Point with Raju Rayavarapu of DNAnexus
From Illumina to Advocacy: Mike Kreitzinger on the Future of Clinical Genomics
Amplifying the Expert: Jing Gao on Illumina's Connected Insights
The End of Animal Testing? Vivodyne Scales Human Tissue with CEO Andrei Georgescu
How Liquid Biopsy Is Becoming Standard of Care with Rita Shaknovich, CMO, Agilent
Tracking GMOs in the Gene Editing Era: Frédéric Debode on the Science of GMO Detection
From Discovery to Translation: Bruker's Bold New Play in Spatial with Joe Beechem and Oliver Braubach
Tagomics Wins NHS Grant, Unveils De-Methylation Platform for Early Cancer Testing with Rob Neely, CSO
From Paris to the Pentagon: Sophie Peresson Maps Biosecurity’s New Landscape
From Mitochondria to Protein Degradation: Mike Kiebish on BPGbio’s "Biology First" Vision
The Grammar of RNA: Gavin Knott on Gene Editing and Structural Biology in the Age of AI
The Third Way: Christian Schafmeister’s Spiroligomer Revolution
Can Math and AI Replace Some Biology in Drug Discovery? with Aridni Shah, Immunito AI
$10 Genome, $8 Coffee: Rethinking the Economics of Life Science Tools with Stephane Budel, DeciBio
Quantum Scale: A New Era for Single-Cell Analysis with Giovanna Prout
Building Intuition at the Nanoscale: Steve McCloskey of Nanome on the VR Future of Science
Beyond the $100 Genome--the Everyday Sequencing Revolution You Missed: Mark Budde, Plasmidsaurus
What Next for LDTs? A Conversation with Sarah Overton of Velsera
AI’s Quiet Revolution in the Pharma Supply Chain with Chris Petersen, Scientist.com
We've Been Misclassifying Childhood AML for Years: Jeffery Klco, St. Jude's
Aaron Viny: A 21-Year Leukemia Survivor on the Frontlines of Epigenetic Cancer Research
Toward Disease Sub-typing with Ben Busby, DNAnexus